Cytek Biosciences, Inc. — Director's Dealing 2021

Jul 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: DENG FENG (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-22	Common Stock	C	147933	—	Acquired	147933	Indirect
2021-07-22	Common Stock	C	4168777	—	Acquired	4168777	Indirect
2021-07-22	Common Stock	C	443800	—	Acquired	443800	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Series A Preferred Stock	$	C	147933	Disposed		Common Stock (147933)	Indirect
2021-07-22	Series C Preferred Stock	$	C	4168777	Disposed		Common Stock (4168777)	Indirect
2021-07-22	Series D Preferred Stock	$	C	443800	Disposed		Common Stock (443800)	Indirect

Footnotes

F1: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

F2: Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V.